A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

Maarten Leusink; Anke H Maitland-van der Zee; Bo Ding; Fotios Drenos; Erik Pa van Iperen; Helen R Warren; Mark J Caulfield; L Adrienne Cupples; Mary Cushman; Aroon D Hingorani; Ron C Hoogeveen; G Kees Hovingh; Meena Kumari; Leslie A Lange; Patricia B Munroe; Fredrik Nyberg; Pamela J Schreiner; Suthesh Sivapalaratnam; Paul Iw de Bakker; Anthonius de Boer; Brendan J Keating; Folkert W Asselbergs; N Charlotte Onland-Moret

doi:10.2217/pgs.16.8

A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

Maarten Leusink, Anke H Maitland-van der Zee, Bo Ding, Fotios Drenos, Erik Pa van Iperen, Helen R Warren, Mark J Caulfield, L Adrienne Cupples, Mary Cushman, Aroon D Hingorani, Ron C Hoogeveen, G Kees Hovingh, Meena Kumari, Leslie A Lange, Patricia B Munroe, Fredrik Nyberg, Pamela J Schreiner, Suthesh Sivapalaratnam, Paul Iw de Bakker, Anthonius de BoerBrendan J Keating, Folkert W Asselbergs, N Charlotte Onland-Moret

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.

PATIENTS & METHODS: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.

RESULTS: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 × 10(-4)).

CONCLUSION: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.

Original language	English
Pages (from-to)	583-91
Number of pages	9
Journal	Pharmacogenomics
Volume	17
Issue number	6
DOIs	https://doi.org/10.2217/pgs.16.8
Publication status	Published - Apr 2016

Access to Document

10.2217/pgs.16.8

Cite this

Leusink, M., Maitland-van der Zee, A. H., Ding, B., Drenos, F., van Iperen, E. P., Warren, H. R., Caulfield, M. J., Cupples, L. A., Cushman, M., Hingorani, A. D., Hoogeveen, R. C., Hovingh, G. K., Kumari, M., Lange, L. A., Munroe, P. B., Nyberg, F., Schreiner, P. J., Sivapalaratnam, S., de Bakker, P. I., ... Onland-Moret, N. C. (2016). A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics, 17(6), 583-91. https://doi.org/10.2217/pgs.16.8

@article{7ad17492184e453b93ef83ba23be2956,

title = "A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering",

abstract = "AIM: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.PATIENTS \& METHODS: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.RESULTS: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95\% CI: 0.0171-0.0617, p = 5.37 × 10(-4)).CONCLUSION: The GRS was associated with statin response, but the small effect size (˜2\% of the average low-density lipoprotein cholesterol reduction) limits applicability.",

author = "Maarten Leusink and \{Maitland-van der Zee\}, \{Anke H\} and Bo Ding and Fotios Drenos and \{van Iperen\}, \{Erik Pa\} and Warren, \{Helen R\} and Caulfield, \{Mark J\} and Cupples, \{L Adrienne\} and Mary Cushman and Hingorani, \{Aroon D\} and Hoogeveen, \{Ron C\} and Hovingh, \{G Kees\} and Meena Kumari and Lange, \{Leslie A\} and Munroe, \{Patricia B\} and Fredrik Nyberg and Schreiner, \{Pamela J\} and Suthesh Sivapalaratnam and \{de Bakker\}, \{Paul Iw\} and \{de Boer\}, Anthonius and Keating, \{Brendan J\} and Asselbergs, \{Folkert W\} and Onland-Moret, \{N Charlotte\}",

year = "2016",

month = apr,

doi = "10.2217/pgs.16.8",

language = "English",

volume = "17",

pages = "583--91",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

Leusink, M, Maitland-van der Zee, AH, Ding, B, Drenos, F, van Iperen, EP, Warren, HR, Caulfield, MJ, Cupples, LA, Cushman, M, Hingorani, AD, Hoogeveen, RC, Hovingh, GK, Kumari, M, Lange, LA, Munroe, PB, Nyberg, F, Schreiner, PJ, Sivapalaratnam, S, de Bakker, PI, de Boer, A, Keating, BJ, Asselbergs, FW & Onland-Moret, NC 2016, 'A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering', Pharmacogenomics, vol. 17, no. 6, pp. 583-91. https://doi.org/10.2217/pgs.16.8

TY - JOUR

T1 - A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

AU - Leusink, Maarten

AU - Maitland-van der Zee, Anke H

AU - Ding, Bo

AU - Drenos, Fotios

AU - van Iperen, Erik Pa

AU - Warren, Helen R

AU - Caulfield, Mark J

AU - Cupples, L Adrienne

AU - Cushman, Mary

AU - Hingorani, Aroon D

AU - Hoogeveen, Ron C

AU - Hovingh, G Kees

AU - Kumari, Meena

AU - Lange, Leslie A

AU - Munroe, Patricia B

AU - Nyberg, Fredrik

AU - Schreiner, Pamela J

AU - Sivapalaratnam, Suthesh

AU - de Bakker, Paul Iw

AU - de Boer, Anthonius

AU - Keating, Brendan J

AU - Asselbergs, Folkert W

AU - Onland-Moret, N Charlotte

PY - 2016/4

Y1 - 2016/4

N2 - AIM: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.PATIENTS & METHODS: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.RESULTS: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 × 10(-4)).CONCLUSION: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.

AB - AIM: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.PATIENTS & METHODS: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.RESULTS: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 × 10(-4)).CONCLUSION: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.

U2 - 10.2217/pgs.16.8

DO - 10.2217/pgs.16.8

M3 - Article

C2 - 27045730

SN - 1462-2416

VL - 17

SP - 583

EP - 591

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 6

ER -

A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

Abstract

Access to Document

Fingerprint

Cite this